Abatacept til behandling af reumatoid artritis

Henrik Nielsen; Annette Hansen

Abatacept til behandling af reumatoid artritis

Translated title of the contribution: Abatacept in the treatment of active rheumatoid arthritis

Henrik Nielsen, Annette Hansen

Department of Clinical Medicine

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

Abatacept (CTLA4Ig) is a human fusion protein which consists of a cytotoxic lymphocytic-associated type 4 antigen which is bound to the Fc part of the IgG1. Abatacept binds to CD80/CD86 on antigen-presenting cells thus blocking the co-stimulatory signal to the naïve T cells and interfering with a central inflammatory rheumatoid arthritis signal pathway.
Udgivelsesdato: 2009-Jan

Translated title of the contribution	Abatacept in the treatment of active rheumatoid arthritis
Original language	Danish
Journal	Ugeskrift for læger
Volume	171
Issue number	4
Pages (from-to)	214-7
Number of pages	4
ISSN	0041-5782
Publication status	Published - 2009

Bibliographical note

Keywords: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Immunoconjugates; Immunosuppressive Agents; Treatment Outcome

Cite this

@article{0ee67830835811df928f000ea68e967b,

title = "Abatacept til behandling af reumatoid artritis",

abstract = "Abatacept (CTLA4Ig) is a human fusion protein which consists of a cytotoxic lymphocytic-associated type 4 antigen which is bound to the Fc part of the IgG1. Abatacept binds to CD80/CD86 on antigen-presenting cells thus blocking the co-stimulatory signal to the na{\"i}ve T cells and interfering with a central inflammatory rheumatoid arthritis signal pathway. Udgivelsesdato: 2009-Jan",

author = "Henrik Nielsen and Annette Hansen",

note = "Keywords: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Immunoconjugates; Immunosuppressive Agents; Treatment Outcome",

year = "2009",

language = "Dansk",

volume = "171",

pages = "214--7",

journal = "Ugeskrift for l{\ae}ger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "4",

}

TY - JOUR

T1 - Abatacept til behandling af reumatoid artritis

AU - Nielsen, Henrik

AU - Hansen, Annette

N1 - Keywords: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Immunoconjugates; Immunosuppressive Agents; Treatment Outcome

PY - 2009

Y1 - 2009

N2 - Abatacept (CTLA4Ig) is a human fusion protein which consists of a cytotoxic lymphocytic-associated type 4 antigen which is bound to the Fc part of the IgG1. Abatacept binds to CD80/CD86 on antigen-presenting cells thus blocking the co-stimulatory signal to the naïve T cells and interfering with a central inflammatory rheumatoid arthritis signal pathway. Udgivelsesdato: 2009-Jan

AB - Abatacept (CTLA4Ig) is a human fusion protein which consists of a cytotoxic lymphocytic-associated type 4 antigen which is bound to the Fc part of the IgG1. Abatacept binds to CD80/CD86 on antigen-presenting cells thus blocking the co-stimulatory signal to the naïve T cells and interfering with a central inflammatory rheumatoid arthritis signal pathway. Udgivelsesdato: 2009-Jan

M3 - Tidsskriftartikel

C2 - 19174034

SN - 0041-5782

VL - 171

SP - 214

EP - 217

JO - Ugeskrift for læger

JF - Ugeskrift for læger

IS - 4

ER -